Details of the Drug Combination

General Information of Drug Combination (ID: DCXHPP2)

Drug Combination Name
Nintedanib AT13387
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Nintedanib   DMMQ2OW AT13387   DM2B9E0
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 37.133
Bliss Independence Score: 39.216
Loewe Additivity Score: 9.907
LHighest Single Agent (HSA) Score: 15.008

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nintedanib
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [3]
Ovarian neoplasm N.A. Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Indication(s) of AT13387
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [5]
AT13387 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
AT13387 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
mRNA-capping enzyme (RNGTT) OT59E0KX MCE1_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
3 Nintedanib FDA Label
4 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6 Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.
7 RNA-binding proteins and heat-shock protein 90 are constituents of the cytoplasmic capping enzyme interactome. J Biol Chem. 2018 Oct 26;293(43):16596-16607. doi: 10.1074/jbc.RA118.004973. Epub 2018 Aug 30.